A short term exposure to resveratrol at high dosages exerts a remarkable cardioprotective effect. Whether a long-term exposure to resveratrol at low dosages that can be obtained through consumption of a resveratrol-rich diet is beneficial to heart diseases is unknown. We tested the effects of a resveratrol-enriched diet on cardiovascular remodeling of chronic heart failure (CHF) in rats resulting from permanent ligation of left coronary artery. Two weeks after surgery, rats were start to feed with either a resveratrol-enriched (R; 5mg/kg/day; n=23) or normal (Control; n=23) diet for next 10 months. Serial echocardiography in Control showed a significant decline in LV Ejection fraction, increases in LV end-systolic and end-diastolic volumes and expansion in myocardial infarct from pretreatment values. In R, compared to Control, there were substantial improvements in those parameters. End-point LV pressure-volume loop analysis showed a significantly improved LV systolic function and AV-coupling, an index of energy transfer efficacy between the heart and aortic tree, in R compared to Control (p<0.05). Aortic pulse wave velocity, a measure of arterial stiffness, was significantly lower in R (389±15 cm/sec; p<0.05) compared to Control (489±38). These results demonstrated that long-term dietary resveratrol supplement reduces cardiovascular structural and functional deterioration in CHF.
Introduction
Chronic heart failure (CHF) continues to be a major cause of morbidity and mortality (Xu et al. 2010) . The prevalence of CHF reaches 20% in older population (Dickstein et al. 2008 ). In the US, the estimated annual cost of health care attributable to CHF exceeds $35 billion (Stewart et al. 2002 and Rosamond et al. 2008) . Despite the remarkable progress in CHF treatment over the last two decades, the overall annual mortality associated with CHF remains high, at around 10% (Neubauer 2007 and Heart Failure Society of America Practice Guideline 2006) , and the quality of life among survivors becomes dramatically compromised as the disease progresses (Juenger et al. 2002 and Hobbs et al. 2002) . Thus, a search for novel therapeutic interventions to improve the course of CHF continues.
Beneficial effects of resveratrol, a red wine extract, in many pathological conditions, disease pre-cursors, and aging in different organs and species have been well documented (Guerrero et ). Compared to these high dosages, the dietary dosage of resveratrol via consumption of certain fruit or red wine is merely around 5mg/kg/day. On the other hand, regardless of dosages, most of the pre-clinical studies were conducted within relatively short-term (less than 3 months) and exposure times to resveratrol have ranged from minutes to 3 months. Despite the popularity of dietary supplementation with resveratrol (most at dietary dosages) in the healthconscious public, especially among patients with cardiovascular diseases, there is no data on whether long-term (>3 month) consumption of resveratrol at dietary dosages has any beneficial effects in CHF. Thus, the effects of long-term consumption of resveratrol-rich diet on progress of chronic diseases, i.e., cardiac remodeling of CHF, is unknown. We investigated the impact of long-term dietary supplementation with resveratrol at a low dose (5mg/kg/day) on cardiac structural and functional remodeling in CHF induced by MI in rats.
The post-MI CHF rat model has a close resemblance to CHF in humans. The interactions among oxidative stress, inflammation, hypertrophy, arrhythmia, fibrosis, chamber dilatation, infarct expansion and functional deterioration that have been characterized in this model (Elsner and Riegger 1995; Gaballa and Goldman 2002; Goldman and Raya 1995) Madison, WI). Resveratrol (> 98%) was purchased from Orchid Pharmaceuticals (Aurangabad, India) and mixed to the Standard NIH rat chow (Dyets Inc., Bethlehem, PA). The resveratrol enriched diet was isocoloric with a regular diet and contained 0.008~0.01% of resveratrol. In R group, rats received resveratrol enriched diet beginning at 2 weeks after coronary ligation, and continued for next 10 months. The target daily dosage for resveratrol in was 5mg/kg. In order to maintain this dosage, the daily food consumption was assessed and resveratrol concentration in food was accordingly adjusted every 3 months. Animals were inspected daily for signs of moribundity by a person blinded to dietary assignments. Moribund animals were euthanized, and their hearts were harvested for histological measurements. Daily records of dead or euthanized animals were used to calculate continuous mortality curves. Echo was repeated bi-monthly following the initiation of treatment. At the end of 10-month observation period, invasive hemodynamic measurements were performed following the completion of final Echo. Rats were then euthanized and their hearts and thoracic aortas were harvested for histological evaluation.
Coronary Artery Ligation
The surgical procedure was performed as previously described (Ahmet et al. 2004) .
Echocardiography (Echo)
Echo was repeated bi-monthly in all rats following the initiation of treatment. Echo (Sonos 5500, a 12-MHz transducer; Hewlett Packard, Andover, MA) was conducted under light anesthesia with isofluorane (2% in oxygen) via face mask as described previously (Ahmet et al. 2004 ). In brief, parasternal long axis views were obtained and recorded to ensure that the mitral and aortic valves and the apex were visualized. Short axis views were recorded at the midpapillary muscle level. Endocardial area tracings, using the leading edge method, were performed in a 2D-dimensional mode (short and long axis views) from digital images captured on cine loop to calculate end diastolic and end systolic LV areas. End-diastolic volume (EDV) and end-systolic volume (ESV) were calculated by a Modified Simpson's method. EF was then derived as EF=100*(EDV-ESV)/EDV. LV mass (LVM) was calculated from a 2D mode. The MI size at the mid-papillary muscle level was estimated from 2D short axis LV images and expressed as a percentage of the LV endocardial circumference. Infarct area was identified as a sharply demarcated section of the LV free wall that failed to thicken during systole. The length of the akinetic part (MI area) of the LV endocardial circumference was measured from freezeframe images at end-diastole. Posterior wall thickness was measured from M-mode. All measurements were made by a single observer who was blinded to the identity of the tracings.
All measurements were offline averaged over three to five consecutive cardiac cycles. The reproducibility of measurements was assessed in two sets of baseline measurements in 10 randomly selected rats, and the repeated measure variability did not exceed ±5%. Percent D r a f t 7 changes of ESV, EDV, EF and MI size from pre-treatment baseline value (at 2 weeks after surgery) were calculated and presented for all the time-points.
Hemodynamic Measurements
Invasive hemodynamic measurements were performed at the end of 10-month observation period. LV pressure-volume loop analyses were conducted as described previously (Ahmet et al. 2005) . Rats were anesthetized with isoflurane (2% in oxygen), intubated, and ventilated.
Following hemodynamic indices were reported: EF, +dP/dt, -dP/dt, End-diastolic pressure (EDP), Isovolumic relaxation time constant (τ), End-systolic elastance (Ees), Preload recruitable stroke work (PRSW), End-diastolic stiffness (Eed), Arterial elastance (Ea) and Arterioventricular coupling (AV coupling).
Pulse Wave Velocity (PWV)
PWV was measured at the same time as cardiac LV pressure-volume loop analyses as described previously (Ahmet et al. 2011) . Briefly, the left femoral artery was isolated, ligated, and a 1F combined pressure-conductance catheter (Millar Instruments Inc., Houston, TX) was inserted and advanced to the thoracic aorta (exactly 100 mm from the incision). After recording of several pressure waves and corresponding ECGs, the catheter was withdrawn for exactly 50 mm and data recording was repeated. Using the R wave of the ECG as a time marker, the average time between R waves and starting points of five corresponding pressure waves at thoracic and abdominal sections of aorta (exactly 50 mm separated) were measured. The transit time of the pressure wave from upper thoracic aorta to lower abdominal aorta was calculated as the time difference between two measurements. Using the distance between two points of measurement, the PWV was calculated as 50 mm/transit time.
Histological Acquisition
Histological staining and analyses were performed as described previously (Ahmet et al. 2011 ). In brief, the hearts were isolated and weighed. Hearts were further cut into two pieces through the short axis. The basal half was fast frozen and stored at -80 0 C, and the apical half was used for histological analysis. Myocardial tissue segments and aortae were imbedded in the paraffin, sectioned (5 µm 
Body Weight and Heart Rate
The body weight was similar among three groups at all the time points. The daily average resveratrol consumption was 5±1mg/kg for whole observation period and the resveratrol diet did not affect the rate of body growth. Heart rate was not different among groups. Table 2 lists the LV pressure-volume loop parameters prior to sacrifice after 10-month of treatment. Figure reduction in PRSW indicated a pronounced systolic LV pump dysfunction; a 4.7-fold elevation in Eed reflected an increased diastolic LV stiffness; and a 2-fold increase in AV-coupling reflected a severe inefficiency in transfer of energy from the heart to the arterial tree. In R, both PRSW and AV-coupling returned to their respective levels in Sham and were significantly different compared to that of Control. Eed did not differ between R and Control.
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D r a f t
At the end of 10-month of observation period, HW/BW ratio, myocyte density, myocyte diameter and collagen fraction of the LV posterior wall were significantly different between Sham and Control, indicating a significant remodeling of LV myocardial structure. None of these parameters differed between Control and R (Table 2) . Figure 4 shows the PWV at the end of 10-month observation period prior to sacrifice. PWV was significantly lower in Sham (377±12 cm/sec; p<0.05) compared to Control (489±38 cm/sec), indicating a significant stiffening of arterial tree in the setting of heart failure. In R, it was 389±15 cm/sec, i.e., at the level of Sham, and significantly different compared to Control (p<0.05). The collagen content of thoracic aorta, measured as a fractional area of tunica media, was not significantly different among 3 groups. The lumen diameter and Intima-media wall thickness of thoracic aorta did not differ between R and Control (Table 2) . 
Aortic Stiffness and Morphology
Mortality
DISCUSSION
Resveratrol, a red wine extract, had been studied extensively in various diseases and aging models during the last decade (Guerrero et al. 2009 ). It also had been studied thoroughly in all D r a f t 13 types of cardiovascular disease models, i.e., ischemia-reperfusion injury, myocardial infarction, hypertrophy, arrhythmias and heart failure. These studies showed that resveratrol, either given before or after manifestation of disease, could prevent or attenuate the disease progress (Chen et al. 2008; Chong et al. 2015; Hung et al. 2002; Shen et al. 2006; Kanamori et al. 2013; Lin et al. 2008; Liu et al 2005; Wojciechowski et al 2010; Xuan et al. 2012) . Those remarkable effects were achieved at dosages of resveratrol that many times higher than the amount possibly obtained through daily consumption of resveratrol-rich diet.
Our results showed for the first time that resveratrol, even at a low dosage as a dietary supplement, when used for long term, was beneficial to cardiac structural remodeling and functional decline that accompany with chronic heart failure. In rats, following permanent coronary artery ligation, repeated echocardiography showed that long-term resveratrol dietary supplementation significantly reduced LV functional deterioration through increasing LV contractility which was evident from the reduction in the LV end-systolic volume (ESV).
Invasive measurements at the end of 10-month of treatment also showed a significantly improved LV systolic function (PRSW) and energy transfer efficacy between heart and arterial tree (AV-coupling).
Also, chronic, low dose resveratrol prevented the elevation of PWV which is an indication of the stiffening of arterial tree that manifests following CHF. PWV is not only an important index for arterial stiffness but also considered an independent predictor for future cardiovascular showed that low dose of resveratrol in dietary supplement, was still beneficial to vascular remodeling when used for long term. Lack of effect on aortic collagen composition in our study suggests that resveratrol might attenuate the vascular remodeling through improvements of endothelial function or vascular smooth muscle cell stiffening. The beneficial effect of resveratrol in arterial tree might be one of the reasons for the improvements in cardiac systolic function and better energy transfer efficacy while there were lack of significant effect on accumulated mortality, myocardial infarct expansion and LV diastolic functional parameters.
Nevertheless, the exact mechanism for those beneficial effects of resveratrol is still elusive and out of scope of this study.
Our results are not contradictory to previously published studies that targeting heart failure with lower dosages of resveratrol (Burstein et al. 2007; Magyar et al. 2012; ).
These studies showed no improvements in cardiac functional parameters after resveratrol treatment for up to 3 months. Based on the fact that we started to observe significant improvements in cardiac functional parameters only after more than 4 months of treatment, with a slightly prolonged exposure time, these studies could have different outcomes. Our results indicated that it needs a longer exposure time for dietary level of resveratrol to exert its full beneficial effect.
The potency of resveratrol against cardiovascular remodeling in our study is indeed less dramatic than these reported in studies at high therapeutic dosages. Although, toxicity of resveratrol has not been reported for high therapeutic dosages, a lower dosage which can mimic a Collagen Fraction of Medium (%) 11.2±1.0 9.1±0.7 9.2±0.6
